Max Konig (@MaxKonigMD) header
Max Konig (@MaxKonigMD) profile picture

Rheumatologist @JohnsHopkins | via Berlin & Boston | CAR-T cells & bispecific antibodies; Antigen-specific therapies for autoimmune diseases | https://teapawt.org/t.co/qbYtSPzHpV

Baltimore, MD
Joined February 2016
Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)Photo by Max Konig (@MaxKonigMD)
2023: The rise of precision cellular therapies. In this Year in Review, I highlight 3 major advances set to transform the treatment of autoimmune and rheumatic diseases. From CAR-T cells to antigen-specific, precision immunotherapies. Link: rdcu.be/dvsaG
5
27
3
120
16,045
Max Konig retweeted
Selective CAR-T for the win? Chimeric autoantigen T cell receptor (CATCR)-T cells targeting PR3 were able to selectively deplete PR3-producing B cells, leaving the other ones alone Possibly all the benefit with none of the harms? Currently #inmice If the future is awesome, this will be it @RheumNow #ACR26 Ab#0928 #ACRBest
4
14
806
.@MaxKonigMD with his lab team: Colin Gliech, Jin Liu, & Brock Moritz ✨
1
3
258
Download our large database of funding opportunities for early-career faculty and researchers Download it here: research.jhu.edu/rdt/funding… 433 funding opportunities.
2
181
4
770
76,021
Targeting autoreactive B cells in SLE with anti-9G4 synthetic immune receptor T cells bit.ly/4p4uQqJ
12
41
7,900
Join me, @MaxKonigMD, Peter A. Merkel, MD, MPH and Cory A. Perugino DO in Los Angeles on 12/6 for the Rheum Forum! More information can be found here: events.vindicocme.com/en/15k…
2
3
527
Love how the team is highlighted in our lab. Video: Abigail McGahan, @JinLiuMD, Kennedy Cleage in the natural science habitat
1
2
3
275
I promise we do not all work in the dark. Portraits: Colin Gliech, Kyle Kaeo
1
2
177
Sat., Nov. 15 in Philly - Join me, @MaxKonigMD, Peter A. Merkel, MD, MPH, & Cory A. Perugino, DO for a free half day meeting on cutting edge advances in treatment of IgG4RD and AAV. More info & registration: events.vindicocme.com/en/15k…
2
7
515
Colleague Prof. Max Konig and Hopkins colleagues shows that anti-9G4 precision cellular therapies provide a strategy to selectively target pathogenic B cells in lupus, while minimizing risks of infection and cytokine-related toxicities. Read more here: biorxiv.org/content/10.1101/…
1
12
1
69
16,953
The title I think was a placeholder🤣 Come see: "Evolving Bispecific T-cell Engagers for the Treatment of Autoimmune Diseases" ACR Basic Science Conference #ACR2025 #TCE #PrecisionImmunotherapy
.@maxkonigMD will provide updates on using T-cell engineering as immunotherapy treatments at #ACR2025, including the use of this therapy to create an ‘immune reset’ in lupus.
1
2
14
1,390
We are excited to share our work describing the first cellular #precision immunotherapies for lupus (#SLE): anti-9G4 CAR-T cells and cTCR-T cells to target autoreactive B cells, but sparing normal ones. These therapies aim to control disease without increasing infection risk.🦠
3
5
2
22
3,324
An amazing team effort across @JohnsHopkinsDOM @hopkinskimmel led by exceptional PhD candidate @JinLiu20221741. We will share more soon.
3
231
Max Konig retweeted
We are excited to shared our latest work on bioRxiv: “Precision targeting of autoreactive 9G4 idiotope B cells in systemic lupus erythematosus (SLE) using engineered CAR- and cTCR-T cells”. Here’s a snapshot of what we did + why it matters: The problem: Current B-cell depleting therapies (e.g., CD19 CAR-T) show transformative potential in SLE but carry substantial risk of infection and cytokine‐mediated toxicities. In SLE, B cells expressing IGHV4-34-derived BCRs (which carry the 9G4 idiotope, "9G4id") are a major source of pathogenic autoantibodies, but these cells are expandable in health. What we did: To exploit this, we developed engineered 9G4-targeted T cells that selectively target 9G4id B cells, testing both anti-9G4 CAR-T cells and anti-9G4 chimeric T cell receptor (cTCR)-T cells. What we found: We show that both anti-9G4 CAR‐T cells and anti-9G4 cTCR‐T cells eliminated autoreactive 9G4id B cell lines and 9G4id B cells from patients with lupus with equal potency, while sparing non-9G4 B cells. This was associated with much lower cytokine release compared to conventional CD19 CAR-T cells that deplete the total B cell pool. We also found that anti-9G4 cTCR-T cells showed significantly less cytokine release compared to anti-9G4 CAR-T cells despite similar potency, suggesting a safer profile. Why this matters: This is a move toward precision cellular therapy in autoimmune disease: instead of wiping out all B cells, we can target the “bad actor” subset. It offers the potential to treat SLE (and other 9G4id-associated diseases like cold agglutinin disease and various B cell cancers) while avoiding immunosuppression and reducing the risk of infection. We hope this work opens the door for safer immune-effector cell therapies in autoimmunity—not just oncology. This work would not have been possible without my PI's guidance @MaxKonigMD and collaborative team effort across @jhrheumatology, oncology, pathology, and neurosurgery at Johns Hopkins Medicine.
1
3
238
Science cannot thrive without the next generation.
57
632
50
3,110
257,882
Destroying leading scientific institutions one step at a time so we can funnel more billions to SpaceX?
Last year, $9B of the $35B that the National Institutes of Health (NIH) granted for research was used for administrative overhead, what is known as “indirect costs.” Today, NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%, above what many major foundations allow and much lower than the 60%+ that some institutions charge the government today. This change will save more than $4B a year effective immediately.
2
3
15
2,528
What are the implications for CAR-T cell therapy for autoimmune diseases? 1- we need safety switches 2- we need targeted editing approaches, not just random integration 3- we need to favor therapies that are rejected (e.g., most allogenic CAR-T cells get rejected) All exist.
A woman with multiply relapsed multiple myeloma had complete remission with cilta-cel, but a low-grade T-cell lymphoma soon developed in the GI tract that contained an insertion of the CAR construct disrupting expression of p53. Read the Brief Report: nej.md/40Yq3gO
3
6
16
1,818
The brain worms are now in charge of science and medicine in the United States. Forget curing cancer, we will bring back iron lungs and infant paralysis, suffocating children with diphtheria, and the snake oils against fully preventable diseases.
THE CDC HAS REMOVED ALL VACCINE INFORMATION SHEETS FROM ITS WEBSITE These are required to be given by pediatricians to families at time of vaccination. So - I guess that’s it!
1
1
11
1,377
I hope American voters realize how insane and dangerous it is for Trump to threaten another NATO ally to give up territory. Suppressing science, preventing communication about a looming pandemic, trying to overwrite constitutional rights. This is doing irreparable harm to the US.
Greenland is not for sale after all! FT: Trump had call with Danish PM Frederiksen about Greenland takeover. Five senior European officials describe call as "horrendous" with Trump being aggressive after Denmark refused sale. 1/
3
9
1,695